Recent efforts targeting the PD1/PD-L1 axis using monoclonal antibodies demonstrate that anti-tumor effect is possible by shielding endogenous immune cells from immunosuppressive signaling (56, 57). The gene discussed is PDCD1; the disease is neoplasm.